The pharma industry is facing an opportunity to overcome rare and orphan disease patient resistance and build long-term relationships through support programs specifically designed to best serve these populations and improve patient outcomes.
Tag Archive for: orphan drugs
Without question, there has been significant progress in pinpointing treatments and accelerating rare disease diagnosis, largely due to the precision of data-driven commercial strategies and the speed of digital clinical trials.
Even with the COVID-19 emergency measures, payers still had an eye on the potential flood of gene therapies for rare diseases brewing in the pipeline, and were pondering new ways to pay for them.